Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.63 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31212433 | 0.85 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2LMNANPSR1 | |
| SCHEMBL31212426 | 0.85 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2LMNANPSR1 | |
| SCHEMBL5461736 | 0.82 | MEN1 (0.70) | MEN1KMT2ASMN1; SMN2LMNANPSR1 | |
| SCHEMBL17628468 | 0.82 | KMT2A (0.70) | MEN1KMT2ASMN1; SMN2LMNANPSR1 | |
| SCHEMBL5915300 | 0.80 | MEN1 (0.75) | MEN1KMT2ASMN1; SMN2LMNANPSR1 | |
| SCHEMBL30361161 | 0.79 | SMN1; SMN2 (0.77) | NPBWR1MCHR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14470092 | 0.78 | MEN1 (0.81) | MEN1KMT2ASMN1; SMN2LMNANPSR1 | |
| SCHEMBL14469937 | 0.78 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2LMNANPSR1 | |
| SCHEMBL31212429 | 0.78 | MEN1 (0.67) | MEN1KMT2ASMN1; SMN2LMNANPSR1 | |
| SCHEMBL27672498 | 0.75 | VCAM1 (0.64) | VCAM1NPBWR1MCHR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | VCAM1 4392/4885NPBWR1 75/4885MCHR1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.